PRINCETON, N.J., March 4 /PRNewswire/ -- Chronic hepatitis C (HCV) and B (HBV) are the most common causes of chronic viral hepatitis in the United States, posing serious risks for long-term medical complications, especially if left untreated. HBV affects over 2 billion people in the world today while HCV affects approximately 4 million people each year. With this in mind, Strategic Research Institute announces the “Annual Viral Hepatitis in Drug Discovery & Development Summit” scheduled to take place March 22-23, 2005 in Princeton, NJ.
By attending this industrial and networking conference you will be able to interact with many of the leading research scientists and decision-makers from the pharmaceutical/biotech industry, public health, and academic communities working in the area of viral hepatitis of North America and internationally. Some of the topics covered at the event include interferon mechanisms, HCV protease inhibitors, HCV polymerase inhibitors, novel advances in HBV therapeutics and other HCV targets/agents.
Some of the participating companies include Anadys Pharmaceuticals which is the conference lead sponsor, Merck, Schering-Plough, Pfizer, Gilead, Idenix Pharmaceuticals, Bristol-Myers Squibb, Vertex Pharmaceuticals, Rigel, Roche, Medivir, Innogenetics, Valeant Pharmaceuticals and many more.
To request a copy of the conference agenda in PDF format, please contact the conference organizer Glenn Pascual of Strategic Research Institute at gpascual@srinstitute.com or 212.967.0095, ext. 245. Please include full contact information
To become a media partner, please contact Cheryl-Kahan Radhuber at ckahan-radhuber@srinstitute.com
For more information on sponsorship & exhibition opportunities, please contact Bernard Cohen at bcohen@srinstitute.com
Strategic Research Institute
CONTACT: Glenn A. Pascual, Conference Producer, Life Sciences,Strategic Research Institute, Tel: +1-212-967-0095 ext. 245,Fax: +1-212-967-7973, gpascual@srinstitute.com
Web site: http://www.srinstitute.com/